Secondary Prevention in Patients with Ischemic Heart Disease after Myocardial Revascularization
https://doi.org/10.31550/1727-2378-2022-21-6-19-24
Abstract
Objective of the Review: Help the doctor in a conversation with the patient to additionally motivate him to follow the recommendations for secondary prevention in the period after myocardial revascularization.
Key points. The article discusses the main risk factors that contribute to the progression of cardiovascular diseases (overweight and obesity, smoking, physical inactivity, depression and anxiety, dyslipidemia, diabetes mellitus, arterial hypertension), as well as various methods of secondary prevention after myocardial revascularization, based on modern data of evidence-based medicine: weight loss, regular physical training, psychopharmacotherapy, high adherence to drug therapy.
Conclusion. Conducting secondary prevention measures is extremely important for patients after myocardial revascularization, since the progression of coronary artery atherosclerosis continues after surgery. Therefore, in the postoperative period, the likelihood of developing cardiovascular events, in particular, early periprocedural myocardial infarction, stent thrombosis, and late restenosis, remains. Optimal drug and non-drug preventive measures improve the quality of life and improve the prognosis in this category of patients.
About the Authors
S. A. Boldueva
Federal State Budgetary Educational Institution of Higher Education “North-Western State Medical University named after I.I. Mechnikov” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
41 Kirochnaya Str., St. Petersburg, 191015
D. S. Evdokimov
Federal State Budgetary Educational Institution of Higher Education “North-Western State Medical University named after I.I. Mechnikov” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
41 Kirochnaya Str., St. Petersburg, Russian Federation 191015
V. M. Guzeva
State Budgetary Healthcare Institution “Leningrad Regional Clinical Hospital”
Russian Federation
Russian Federation
45 Lunacharsky Ave., build. 2 lit. A, St. Petersburg, 194291
References
1. Fearon W.F., Nishi T., De Bruyne B., Boothroyd D.B. et al. FAME 2 Trial Investigators. Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018; 137(5): 480–7. DOI: 10.1161/CIRCULATIONAHA.117.031907
2. Hueb W., Lopes N., Gersh B.J., Soares P.R. et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010; 122(10): 949–57. DOI: 10.1161/CIRCULATIONAHA.109.911669
3. Giannuzzi P., Temporelli P.L., Marchioli R., Maggioni A.P. et al. Global secondary prevention strategies to limitevent recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch. Intern. Med. 2008; 168(20): 2194–204. DOI: 10.1001/archinte.168.20.2194
4. Rivas-Estany E., Campos Vera N.A. Impact of cardiac rehabilitation in patients after myocardial revascularization. Sports Med. Rehabil. J. 2019; 4(1): 1044.
5. Wan Y.F., Ma X.L., Yuan C., Fei L. et al. Impact of daily lifestyle on coronary heart disease. Exp. Ther. Med. 2015; 10(3): 1115–20. DOI: 10.3892/etm.2015.2646
6. Muromtseva G.A., Kontsevaya A.V., Konstntinov V.V., Artamonova G.V. et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012–2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014; 13(6): 4–11. (in Russian). DOI: 10.15829/1728-8800-2014-6-4-11
7. Mann D.L., Libby P., Bonow R.O., Zipes D.P., eds. Braunwald’s heart disease: a textbook of cardiovascular medicine. Saunders; 2007. (in Russian)
8. Lyamina N.P., Kotelnikova E.V. Physical rehabilitation after percutaneous coronary intervention: new perspectives of rehabilitation programme integration into ambulatory healthcare system. Cardiovascular Therapy and Prevention. 2011; 10(8): 40–4. (in Russian)
9. Belardinelli R., Paolini I., Cianci G., Piva R. et al. Exercise training intervention after coronary angioplasty: the ETICA trial. J. Am. Coll. Cardiol. 2001; 37(7): 1891–900. DOI: 10.1016/s0735-1097(01)01236-0
10. Bubnova M.G., Aronov D.M., Ivanova G.E., Boytsov S.A. et al. The pilot project “Development of the system of rehabilitation of patients with cardiovascular diseases in medical institutions of the Russian Federation”. The results of the three-year follow-up. Bulletin of Rehabilitation Medicine. 2016; 4(74): 2–11. (in Russian)
11. Amaravathi E., Ramarao N.H., Raghuram N., Pradhan B. Yoga-based postoperative cardiac rehabilitation program for improving quality of life and stress levels: fifth-year follow-up through a randomized controlled trial. Int. J. Yoga. 2018; 11(1): 44–52. DOI: 10.4103/ijoy.IJOY57_16
12. Ettehad D., Emdin C.A., Kiran A., Anderson S.G. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957–67. DOI: 10.1016/S0140-6736(15)01225-8
13. Fox K.A., Mehta S.R., Peters R., Zhao F. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004; 110(10): 1202–8. DOI: 10.1161/01.CIR.0000140675.85342.1B
14. Hahn J.Y., Song Y.B., Oh J.H., Cho D.-K. et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMARTDATE): a randomised, open-label, non-inferiority trial. Lancet. 2018; 391(10127): 1274–84. DOI: 10.1016/S0140-6736(18)30493-8
15. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–81. DOI: 10.1016/S0140-6736(10)61350-5
Review
For citations:
Boldueva S.A., Evdokimov D.S., Guzeva V.M. Secondary Prevention in Patients with Ischemic Heart Disease after Myocardial Revascularization. Title. 2022;21(6):19-24. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-6-19-24
Views:
18
Email this article 